Cingulate (CING) Total Current Liabilities (2021 - 2026)
Cingulate's (CING) quarterly Total Current Liabilities came in at $10.3 million in Q4 2025, up 107.41% YoY from $5.0 million in Q4 2024, and up 75.32% on a QoQ basis from $5.9 million in Q3 2025.
Cingulate (CING) Total Current Liabilities (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Total Current Liabilities data on file, last reported at $10.3 million in Q4 2025.
- Quarterly Total Current Liabilities rose 107.41% year-over-year to $10.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.3 million (up 107.41% YoY) and the FY2025 annual result came in at $10.3 million, up 107.41% from the prior year.
- Total Current Liabilities rose to $10.3 million in Q4 2025, from $5.9 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $11.0 million in Q2 2023 to a low of $923505.0 in Q2 2022.
- A 5-year average of $5.2 million and a median of $5.7 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities soared 1090.56% — and 2024, when it sank 81.42%.
- Tracing CING's Total Current Liabilities over 5 years: stood at $1.2 million in 2021, then jumped by 495.98% to $7.0 million in 2022, then surged by 45.82% to $10.2 million in 2023, then sank by 51.38% to $5.0 million in 2024, then surged by 107.41% to $10.3 million in 2025.
- The last three Total Current Liabilities figures came in at $10.3 million (Q4 2025), $5.9 million (Q3 2025), and $5.6 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | 8.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.63 Mn |
| Dec 31, 2025 | 10.31 Mn |
| Sep 30, 2025 | 5.88 Mn |
| Mar 31, 2025 | 5.62 Mn |
| Dec 31, 2024 | 4.97 Mn |
| Sep 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 2.04 Mn |
| Mar 31, 2024 | 2.25 Mn |
| Dec 31, 2023 | 10.23 Mn |
| Sep 30, 2023 | 5.73 Mn |
| Jun 30, 2023 | 10.99 Mn |
| Mar 31, 2023 | 6.66 Mn |
| Dec 31, 2022 | 7.01 Mn |
| Sep 30, 2022 | 6.41 Mn |
| Jun 30, 2022 | 923,505.00 |
| Mar 31, 2022 | 1.63 Mn |
| Dec 31, 2021 | 1.18 Mn |